Peptides explained in plain language
Not medical advice
FDA-approvedResearch-only

PT-141 vs. Vyleesi: same molecule, different product

Bremelanotide is an FDA-approved prescription drug, and "PT-141" vials sold online are not the same thing.

Key takeaways

  • PT-141 is another name for bremelanotide, the active ingredient in the prescription drug Vyleesi.
  • Vyleesi is FDA-approved only for low sexual desire in premenopausal women, not for men or performance enhancement.
  • Online "PT-141" sold for research use isn't made to drug standards, so dose and purity are unknown.
  • Vyleesi can raise blood pressure for hours after a dose, so a clinician should review your heart health first.

If you have searched for PT-141, you have probably seen two very different things. One is Vyleesi, a prescription drug. The other is a vial of powder sold online as a “research peptide.” The active molecule has the same name, bremelanotide. The products are not the same.

What Vyleesi is approved for

Vyleesi is FDA-approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder. In plain terms, that means low sexual desire that causes real distress and isn’t explained by another health problem, a medicine or relationship issues.

The label is specific about what it is not for. It isn’t approved for women after menopause or for men. It isn’t meant to enhance sexual performance.

Bremelanotide works on melanocortin receptors in the body, which are involved in sexual desire and also in skin pigment. That second role explains one of its side effects.

Known side effects

The official label lists several effects worth knowing about:

  • Nausea: the most common side effect in trials. It is usually worst with the first dose.
  • Blood pressure changes: a short-term rise in blood pressure and drop in heart rate after each dose, usually resolving within about 12 hours.
  • Skin darkening: patches of darker skin, including on the face and gums. This was more common in people with darker skin, and it did not always go away.
  • Other effects: flushing, headache, vomiting and reactions at the injection site.

People with high blood pressure that isn’t controlled, or with heart disease, should not use it.

Get the weekly peptide brief

What changed in the rules, what new research says, and which claims to ignore. One email a week.

What “PT-141” online usually means

Many websites sell bremelanotide labeled “for research use only” or “not for human consumption.” These products aren’t made under the quality rules that apply to approved drugs. That leads to real risks:

  • The vial may contain more or less than the label says, or a different substance.
  • It may not be sterile, or it may carry bacterial toxins or leftover solvents.
  • A certificate of analysis can be copied or faked.
  • There is no recall system if a batch turns out to be bad.
Vyleesi Online “PT-141”
FDA status Approved prescription drug Not approved for human use
Who it’s for Premenopausal women with HSDD Not labeled for any person
Quality standards Made under drug manufacturing rules No guaranteed standards
Medical oversight Prescriber reviews heart health and other medicines None

Questions to bring to a clinician

  • Do my symptoms fit the condition Vyleesi is approved to treat?
  • Is my blood pressure and heart health a concern?
  • Could any of my current medicines interact with it?
  • Are there other causes of low desire we should look at first?

The bottom line

PT-141 and Vyleesi share a molecule, but only Vyleesi comes with an approved use, a known dose and drug-grade quality. If low desire is bothering you, a clinician can help sort out the cause and talk through whether a prescription makes sense.

This article is for general education and isn’t medical or legal advice. It was written with AI assistance and may contain errors, so check anything that matters against the sources above and with a qualified healthcare professional before starting, stopping or changing any treatment. Why we say this.

Chris Janowski
About the author

Chris Janowski, owner and editor in chief

Chris Janowski is the editor in chief of Peptide Consumer Center. He started the site to give people a plain-language, well-sourced place to learn what peptides are, how they’re regulated and what the evidence actually says. Articles are written with AI assistance and published under his name.

Peptide Consumer Center is owned by Chris Janowski, who also owns PureVitaX, an online store that sells peptides, including several covered on this site. We link to PureVitaX, and Chris benefits when you buy there. Disclosures.